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Abstract
Mild cognitive impairment (MCI) occurs during the pre-dementia stage of Alzheimer’s disease 
(AD) and is characterized by a decline in cognitive abilities that frequently represents a transition 
between normal cognition and AD dementia. Its pathogenesis is not well understood. Here, we 
demonstrate the direct consequences and potential mechanisms of oxidative stress, mitochondrial 
dynamic and functional defects in MCI-derived mitochondria. Using cytoplasmic hybrid (cybrid) 
cell model in which mitochondria from MCI or age-matched non-MCI subjects were incorporated 
into a human neuronal cell line depleted of endogenous mitochondrial DNA, we evaluated the 
mitochondrial dynamics and functions, as well as the role of oxidative stress in the resultant cybrid 
lines. We demonstrated increased expression levels of mitofusin 2 (Mfn2) is markedly induced by 
oxidative stress in MCI-derived mitochondria along with aberrant mitochondrial functions. 
Inhibition of oxidative stress rescues MCI-impaired mitochondrial fusion/fission balance as shown 
by the suppression of Mfn2 expression, attenuation of abnormal mitochondrial morphology and 
distribution, and improvement in mitochondrial function. Furthermore, blockade of MCI related 
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stress-mediated activation of extracellular signal-regulated kinase (ERK) signaling not only 
attenuates aberrant mitochondrial morphology and function but also restores mitochondrial fission 
and fusion balance, in particular inhibition of overexpressed Mfn2. Our results provide new 
insights into the role of the oxidative stress-ERK-Mfn2 signal axis in MCI-related mitochondrial 
abnormalities, indicating that the MCI phase may be targetable for the development new 
therapeutic approaches that improve mitochondrial function in age-related neurodegeneration.
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Introduction
Mild cognitive impairment (MCI) is characterized by a decline in cognitive abilities that is 
noticeable yet not severe enough to completely disrupt an individual’s daily activity, and is 
generally considered to be a transitional phase between normal aging and early dementing 
disorders, especially Alzheimer’s disease (AD) [1–3]. As patients with MCI typically 
convert to definitive AD (probability of 50% within 4 years or at a rate of about 12% per 
year) [4, 5], it is important to consider whether targeting early treatment interventions 
towards MCI patients holds potential merit. Some neuropathologic changes observed in 
MCI partially overlap with the functional alterations seen in AD; for example, neuritic 
plaques in neocortical regions and neurofibrillary tangles (NFT) in the temporal lobe are 
seen in MCI patients [6], and there is significant elevation of oxidative DNA damage in 
peripheral lymphocytes and brain tissues of MCI patients [7–9]. In addition, several gene 
mutations associated with AD have been observed in subjects with MCI including 
polymorphic variation in apolipoprotein E and mutations in presenilin 1 and the amyloid 
precursor protein [10–13]. Although the underlying mechanisms remain elusive, increasing 
evidence indicates an essential role for mitochondrial dysfunction in AD etiology and 
pathology [14]. Interestingly, the impairment of mitochondrial function observed in AD is 
also seen in MCI subjects; this includes decreased cytochrome c oxidase activity [15], 
decreased mitochondrial membrane potential and lower mitochondrial cytochrome c content 
[16]. Thus, although we know that mitochondrial dysfunction may play a critical role in 
MCI pathologies and its development into AD, its underlying mechanisms are not well 
understood.
Mitochondria are dynamic organelles, which engage in repeated cycles of fusion and fission. 
Mitochondrial dynamics (fission and fusion events) are essential for maintenance of 
mitochondrial morphology, appropriate distribution and normal function [17, 18]. In 
mammals, the balance of mitochondrial dynamics is regulated by the large dynamin-related 
GTPases fusion [mitofusin 1 and 2 (Mfn1 and Mfn2) and optic atrophy1 (OPA1)] and 
fission proteins [dynamin-like protein (Drp1) and mitochondrial fission 1 protein (Fis1)] 
[19, 20]. Neurons are particularly reliant on mitochondrial dynamic properties as they 
require mitochondria in the synaptic terminals [21]. Deficiency in either fission or fusion 
reduces mitochondrial trafficking, leading to aberrant distribution of mitochondria and 
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defective cellular function [22, 23]. Disrupted mitochondrial fission/fusion balance is 
consistently involved in neurodegenerative diseases including AD [24, 25]. Although altered 
balance of mitochondrial fission/fusion is involved in AD postmortem brain [25, 26], 
transgenic AD mouse models, and amyloid beta (Aβ)-treated in vitro cell cultures [27, 28], 
the role of mitochondrial dynamic balance in mediating MCI mitochondrial morphology and 
function and its underlying mechanisms have not been explored.
In the present study, we determined whether and how mitochondrial alterations occur in 
MCI-derived mitochondria. Using the cytoplasmic hybrid (cybrid) model in which 
mitochondria from MCI patients or symptom-free, age-matched non-MCI subjects were 
incorporated into human neuronal (SH-SY5Y) cells previously depleted of endogenous 
mitochondrial DNA (mtDNA), we comprehensively evaluated the changes of MCI-specific 
mitochondrial dynamics and mitochondrial function. Our studies provide substantial 
evidence that disturbed mitochondrial dynamics and impaired mitochondrial functions 
contribute to MCI pathology, and may provide an opportunity for developing diagnostic and 
therapeutic advances.
Material and methods
Human subjects and creation of cybrid cell lines
Human subjects for the MCI and Non-MCI group were recruited from the University of 
Kansas Alzheimer’s Disease Center (KU ADC, 7 MCI patients and 7 age-matched Non-
MCI controls). Based on the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria 
[29], MCI diagnosis was made in accordance with the criteria defined by Petersen et al. [5], 
and the patients were classified as 0.5 according to the Clinical Dementia Rating (CDR) 
scale. Non-MCI subjects were without subjective or objective evidence of cognitive 
impairment. The ages of MCI and Non-MCI subject platelet donors were 72.6+2.5 and 
74+3.0 years, respectively. Gender, age and disease status of donor patients are presented in 
supplemental Table S1. This study was approved by the University of Kansas Medical 
Center (KUMC) Institutional Review Board. All subjects provided written informed consent 
to participate in the study.
To create cybrids for this study, Rho0 SH-SY5Y cells lacking mtDNA were obtained from 
the KU ADC Mitochondrial Genomics and Metabolism Core and repopulated with 
mitochondria containing platelet mtDNA from volunteer patients or age-matched controls as 
previously described [30]. Briefly, Rho0 cells were incubated with donor platelets in a 
Dulbecco's Modified Eagle Medium (DMEM)-polyethylene glycol solution. Immediately 
after this, cells were initially placed in DMEM supplemented with 10% non-dialyzed fetal 
bovine serum (FBS), 200µg/ml sodium pyruvate, 150µg/ml uridine, and 1% penicillin–
streptomycin solution to recover. Seven days after the fusion event, cells were switched to a 
selection medium containing 10% dialyzed fetal calf serum without pyruvate and uridine. 
These conditions resulted in selection against Rho0 cells that were not repopulated with 
donor mitochondria. Only cells containing patient platelet mtDNA can regain aerobic 
competence and survive the subsequent selection processes. Following selection, each 
cybrid cell line was maintained in DMEM supplemented with 10% non-dialyzed FBS and 
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1% penicillin-streptomycin solution in a humidified 95% air, 5% CO2 incubator at 37°C for 
over 2 months. Quantitative real-time polymerase chain reaction (rPCR) showed that intact 
mtDNA copies were present in all cybrids without detectable large-scale deletion after many 
passages of cell proliferation (Fig. S1). Cells were treated with the antioxidant drug probucol 
(10µM) (Sigma), ERK1/2 inhibitor PD98058 (10 µM) (Sigma) for 24 hours prior to 
biochemical and molecular assays.
Measurement of enzyme activities associated with respiratory chain complexes and ATP 
levels
The key enzyme activities associated with the mitochondrial respiratory chain, including 
complex I (NADH-ubiquinone reductase), complex II (succinate dehydrogenase), complex 
III (ubiquinol-cytochrome c reductase), complex IV (cytochrome c oxidase, CcO) and citrate 
synthase, were measured in cybrid cell lysates and isolated platelets’ mitochondria as 
described previously [31–33]. ATP levels were measured using an ATP Bioluminescence 
Assay Kit (Roche) following the manufacturer’s instructions and using a Shimadzu (Kyoto, 
Japan) UV1200 spectrophotometer.
Oxidative stress, mitochondrial membrane potential, and mitochondrial morphology 
analysis
Cybrid cells were harvested from 75cm2 flasks and replated at low density onto Lab-Tek 
eight-well chamber slides. To estimate production of reactive oxygen species (ROS), 80% 
confluent cybrid cells were exposed to 2.5µM Mitosox Red, a fluorochrome specific for 
anion superoxide produced in the inner mitochondrial compartment (Molecular Probes) at 
37°C for 30 minutes. To assess mitochondrial membrane potential, cells were co-stained 
with Mitotracker Green (MTGreen) (100nM; Molecular Probes) and tetramethylrhodamine 
methyl ester (TMRM) (100nM; Molecular Probes) at 37°C for 30 minutes. Fluorescence 
from MTGreen is independent of membrane potential, whereas TMRM is sensitive to 
membrane potential. For visualization of mitochondria, cybrid cells were stained with 
Mitotracker Red (200nM; Molecular Probes) at 37°C for 30 minutes before fixation.
Leica TCS SPE confocal scanning microscopes with a 63× 1.4 NA Apochrome objective 
lens (Carl Zeiss MicroImaging, Inc.) were used to photograph cells. Excitation wavelengths 
were 543 nm for Mitosox, TMRM or Mitotracker Red, and 488 nm for MTGreen, 
respectively. Post-acquisition processing was performed with MetaMorph (Molecular 
Devices) and NIH Image J software for quantification and measurement of fluorescent 
signals to assess mitochondrial length and occupied area. Mitochondrial size, shape, density, 
and fluorescent intensity were quantified by an investigator blinded to experimental groups. 
More than 100 clearly identifiable mitochondria from randomly selected 10 to 15 cells per 
experiment were measured in 3 to 5 independent experiments.
Evaluation of intracellular ROS levels was accessed by election paramagnetic resonance 
(EPR) spectroscopy as described in our previous study [34–36]. CMH (cyclic 
hydroxylamine 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine) (100µM) 
was added to cybrid cell culture 30 min before the end of the treatments. After treatments, 
cells were washed with cold PBS, collected, and drawn into glass capillaries. The EPR 
Gan et al. Page 4













spectra were collected, stored, and analyzed with a Bruker EleXsys 540 x-band EPR 
spectrometer (Billerica, MA) using the Bruker Software Xepr (Billerica, MA).
Isolation of mitochondria and immunoblot analysis
Mitochondrial fraction isolated from cybrid cells were suspended in buffer (150mM KCl, 
5mM HEPES, 2mM K2HPO4, 5mM glutamate, 5mM malate, 150mM potassium 
thiocyanate, pH 7.2). Mitochondrial fraction and cell lysate were subjected to 
immunoblotting. Mouse anti-Mfn2 (1:2000, Sigma), rabbit anti-Drp1 (1:3000, Thermo 
scientific), rabbit anti-Opa1 (1:5000, Abcam), rabbit anti-Fis1 (1:3000, Abcam), mouse anti-
Hsp60 (1:5000, Enzo), rabbit anti-phospho-ERK1/2, mouse anti-ERK1/2 (1:2000, Cell 
signaling), rabbit anti-PGC1α (1:2000, Santa Cruz) and mouse anti-β-actin (1:8000, Sigma) 
were used as primary antibodies. Binding sites of primary antibody were visualized with 
horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:5000, life technology) or 
anti-mouse IgG antibody (1:5000, life technology) followed by the addition of enhanced 
chemiluminescence (ECL) substrate (GE Healthcare). Relative quantification of optical 
density for immune reactive bands was performed using NIH Image J software.
Knockdown of Mfn2 expression by siRNA-Mfn2
Cybrid cells were transfected with siRNA targeting human Mfn2 (accession number 
NM012062) or control siRNA(ON-TARGET Plus SMART Pool™, Dharmacon Research) 
using Oligofectamine (Invitrogen) according to the manufacturer’s instructions. Mfn2 
silencing efficiency was evaluated by immunoblotting and immunostaining of Mfn2 protein 
expression at 48 hours after siRNA transfection. In parallel experiments, mitochondrial 
morphology was measured by immunostaining and Mitotracker Red staining.
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis was performed using Statview 
software (SAS Institute, Version 5.0.1). Differences between means were assessed by 
Student’s t-test or one-way analysis of variance (ANOVA) with Bonferroni-Dunn posthoc 
test. P <0.05 was considered significant.
Results
Abnormal Mitochondrial Morphology and Mitochondrial Fission/Fusion Events in MCI 
Cybrid Neurons
Mitochondrial density in whole cell, cell body, and cell processes was lower in MCI cybrid 
cells compared to non-MCI cells (Fig. 1A1–A3). Morphologically, mitochondria in non-
MCI cybrids were rod-like or elongated, and regularly distributed (Fig. 1C), whereas 
mitochondria were obviously more elongated in MCI cybrids. Mitochondrial length was 1.4 
fold longer than non-MCI cybrids in the cell body; this effect was increasingly pronounced 
with greater distance from nuclei, reaching a 1.7 fold relative increase in the neuronal 
process area (Fig. 1B1–B4).
Given that normal mitochondrial fusion and fission balance controls the number, length, and 
tubular shape of mitochondria [37, 38], we tested whether MCI-induced mitochondrial 
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elongation was mediated by impaired mitochondrial fusion and fission events. 
Mitochondrial fractions from each cybrid cell line were isolated to assess fission and fusion 
protein levels by immunoblotting (Fig. 1D–E). As shown in Fig. 1D, compared to non-MCI 
mitochondrial fractions, Drp1 levels were not significantly changed in mitochondrial 
fractions of MCI cybrids, however Mfn2, which controls mitochondrial fusion, was 
increased (1.8 fold) in mitochondria from MCI cybrids (Fig. 1E). In addition, there were no 
significant differences of Fis1 and Opa1 expression levels between non-MCI and MCI-
derived mitochondria (Fig. S2). Thus, in MCI-derived mitochondria alterations in fusion 
protein levels were shifted in a direction that favors mitochondrial fusion.
Mitochondrial Dysfunction in MCI Cybrid Cells
Because mitochondrial dynamics are important for maintenance of mitochondrial function, 
we next evaluated mitochondrial function by assessing key enzyme activity associated with 
respiratory chain activity, mitochondrial membrane potential, and energy production in MCI 
and Non-MCI cybrid cells. Complex I (NADH-ubiquinone reductase), III (ubiquinol-
cytochrome c reductase), and IV (cytochrome c oxidase, CcO) activity (Fig. 2A–C) of MCI 
cybrids (respectively) decreased by 1.6, 1.5, and 1.3 fold, respectively, as compared to non-
MCI cybrids. We did not find significant changes in complex II (succinate dehydrogenase) 
activity in MCI cybrid cells (Fig. S3A). In parallel, ATP levels in MCI cybrids were 
significantly lower than in non-MCI cybrids (Fig. 2D). We also examined citrate synthase 
activity to consider potential differences in mitochondrial enrichment between MCI and 
non-MCI cybrids. Citrate synthase activity was comparable between groups (Fig. S3B). 
Differences in mitochondrial mass are therefore unlikely to account for the observed 
decrease in complex I, III, and IV activities. In addition, we obtained similar results from 
MCI platelet mitochondria showing deficits in mitochondrial respiratory enzyme activities 
(Fig. S4). These results validate abnormalities in platelet mitochondria, which occur as early 
as MCI phase before onset of any symptoms or AD pathology.
Mitochondrial depolarization (reflecting a decreasing membrane potential) resulted in a loss 
of dye from the mitochondria and decreased mitochondrial fluorescence intensity. The 
intensity of TMRM staining was significantly decreased in MCI cybrids as compared to 
non-MCI cybrids (Fig. 2E). The measurement of TMRM staining intensity was normalized 
to Mitotracker Green fluorescence, the values of which for each group were shown in Fig. 
S5, indicating that the validated mitochondrial parameters were comparable among groups.
Given that ROS is generated as a by-product of electron transfer through different 
respiratory chain complexes and that ROS accumulation affects mitochondrial function, we 
tested whether MCI cybrids have abnormal mitochondrial ROS generation and accumulation 
by measuring mitochondrial superoxide production with Mitosox Red. Mitosox staining 
intensity was significantly increased in MCI cybrids compared to non-MCI controls, 
indicating increased levels of mitochondrial ROS in MCI cybrids (Fig.2F). To further 
confirm the oxidative stress status of each cybrid cell line, we employed a highly specific 
EPR assay to quantitatively measure the intracellular ROS levels in Non-MCI and MCI 
cybrids. As shown in Fig. 2G, H, the intracellular ROS levels were significantly elevated in 
MCI cybrids compared to non-MCI cybrids. This data in conjunction with the result of 
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Mitosox suggests an elevation of intracellular ROS production/accumulation in MCI cybrid 
cells containing MCI-derived mitochondria.
Effect of Antioxidant Treatment on Mitochondrial Morphology, Function, and Fission/
Fusion Proteins in MCI Cybrid Cells
Increasing evidence suggests that mitochondrial dysfunction is linked to increased oxidative 
stress [39]. Here, we exploited the direct effects of antioxidant/scavenger properties of 
probucol to determine whether antioxidant treatment prevents or reduces mitochondrial 
dysfunction in MCI cybrid cells. The treatment of Probucol almost abolished ROS 
production as indicated by reduced Mitosox intensity and EPR values as well as improved 
mitochondrial membrane potential (Fig. 3A–E) in MCI cybrids as compared to vehicle-
treated MCI cybrid cells. Importantly, probucol treatment also significantly restored 
complex I activity and ATP levels in MCI cybrid cells (Fig. 3F–G). Taken together, these 
results suggest that antioxidants may benefit MCI-derived mitochondria.
In view of the detrimental effect of oxidative stress on mitochondrial dynamics [40, 41], we 
then assessed the effect of antioxidant treatment with probucol on mitochondrial density, 
length, and morphology. Indeed, probucol treatment resulted in significantly increased 
mitochondrial density and shortened mitochondrial length in MCI cybrid cells compared to 
vehicle treated cybrids (Fig. 4A–B). Abnormal mitochondrial morphology (elongation) in 
MCI cybrids was largely reversed compared to vehicle-treated MCI cybrids (Fig. 4C), 
indicating a protective effect of antioxidant treatment on abnormal mitochondrial 
morphology. We next investigated mitochondrial fusion protein expression in cybrid cells 
following probucol treatment. Probucol treatment significantly decreased Mfn2 expression 
levels, reducing it to the levels found in non-MCI cells (Fig. 4D). These data demonstrate 
antioxidant-mediated recovery of impaired mitochondrial fission and fusion dynamics in 
MCI mitochondria.
Activation of ERK signal pathway contributes to defects in mitochondrial fission/fusion 
dynamics and function in MCI cybrids
Given that oxidative stress induces activation of MAP kinase including extracellular 
receptor kinase (ERK) [42, 43], we next explored a signal pathway involved in regulation of 
mitochondrial fission/fusion dynamics and function [42, 44, 45]. ERK1/2 phosphorylation 
increased by 3–4 folds in MCI cybrids compared to Non-MCI neurons. The addition of 
PD98059, a specific ERK inhibitor largely abolished ERK1/2 phosphorylation (Fig. 5A). 
Total ERK1/2 was not significantly changed in MCI cybrids compared to non-MCI cybrids. 
To determine the effect of oxidative stress on ERK1/2 activation, cells were treated with 
probucol and then analyzed for phospho-ERK1/2. Probucol treatment inhibited ERK1/2 
phosphorylation in MCI cybrid neurons (Fig. 5B), compared to vehicle treatment. Addition 
of PD98059 to MCI cybrid cells also completely suppressed mitochondrial ROS generation 
(Fig. 5C) as well as intracellular ROS production measured by EPR (Fig. 5D–E). Although 
oxidative stress-induced activation of ERK1/2 was described in various types of cells [46, 
47], it is less clear whether oxidative stress-activated ERK1/2 signaling pathway contributes 
to altered mitochondrial dynamics and functions in MCI cybrids. Therefore, we examined 
whether blockade of ERK1/2 activation rescues mitochondrial dysfunction in MCI cybrid 
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mitochondria. Mitochondrial membrane potential was significantly increased in MCI cybrid 
cells in the presence of an ERK1/2 inhibitor (PD980590), as shown by a significantly higher 
intensity of TMRM staining in MCI cybrid cells than in vehicle-treated cells (Fig. 5F).
We next evaluated mitochondrial morphology and mitochondrial fission/fusion protein 
expression levels in cybrid cells treated with PD98059 to determine the effect of ERK1/2 
signal transduction. Mitochondrial density was increased in MCI cybrid cells treated with 
PD98059 compared to vehicle-treated cells (Fig. 5G–H). Morphologically, there was a 
significant reduction in mitochondrial elongation in MCI cybrids (Fig. 5I). Immunoblotting 
of mitochondrial fractions revealed that PD98059 treatment reduced Mfn2 expression to the 
levels seen in non-MCI cybrid cells (Fig. 5J). Thus, our data indicate that inhibition of ERK 
rescues abnormal mitochondrial dynamics responsible for mitochondrial morphology and 
function.
Mfn2-silencing with siRNA Restores Mitochondrial Function and Mitochondrial Fission/
fusion balance in MCI cybrids
To further determine the protective effects of Mfn2 suppression on aberrant mitochondrial 
morphology and function observed in MCI-derived mitochondria, we reduced Mfn2 
expression levels to the non-MCI levels by using siRNA at a selected concentration to 
eliminate the potential detrimental effect of the lack of Mfn2 [48]. Immunoblotting showed 
that Mfn2 expression levels were reduced by 50% in siRNA-treated MCI-cybrid cells 
compared to those treated with unrelated control siRNA (Fig. 6A). Immunostaining with a 
specific Mfn2 antibody confirmed the suppression of Mfn2 expression in siRNA-treated 
MCI cybrid cells (Fig. 6B). Notably, abnormal mitochondrial morphology was attenuated by 
treating with Mfn2-siRNA, as shown by a reduction of mitochondrial elongation in MCI 
cybrids when compared to control siRNA transfection; MCI cybrids displayed almost 
normal rod-like mitochondria following Mfn2 siRNA transfection (Fig. 6B). Mitochondrial 
density and length were significantly increased and decreased, respectively, in Mfn2-siRNA 
transfected cells as compared to control siRNA transfected cybrids (Fig. 6C–D).
Next, we evaluated mitochondrial function with Mfn2-siRNA and control siRNA treatment. 
Deficits in complex IV activity, mitochondrial membrane potential, and intracellular and 
mitochondrial ROS production were reversed by Mfn2-siRNA treatment as compared to 
control siRNA treatment (Fig. 6E–K). These results indicate that preventing Mfn2 
overexpression in MCI-cybrid cells attenuates abnormal mitochondrial morphology and 
function. Thus, enhanced Mfn2 expression in MCI-derived mitochondria may contribute to 
abnormal mitochondrial structure and function.
Discussion
Mitochondrial dysfunction has been widely documented in AD brain and AD mouse models 
[31, 49, 50], but the precise role of such dysfunction in AD remains largely undefined. 
Using the cybrid model, we demonstrate that mitochondrial defects are also present at the 
MCI phase, which often represents a prodromal stage of AD. Importantly, we show a 
potential mechanism in which MCI mitochondria impair mitochondrial fission/fusion events 
through oxidative stress-mediated ERK1/2 signal activation. We also reveal the 
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consequences and impact of MCI-derived mitochondrial defects on mitochondrial function 
in comparison of MCI cybrids with non-MCI cybrids. Consistent with studies performed in 
MCI subjects [15, 51, 52], we demonstrated impaired mitochondrial respiratory chain 
enzyme activity, decreased membrane potential, increased mitochondrial and intracellular 
reactive oxygen species (ROS), and defects in energy metabolism with decreased ATP 
levels in MCI cybrids. Peroxisome proliferator-activated receptor γ coactivator α (PGC1α), 
as a key regulator of energy metabolism, plays important role in mediating changes of 
mitochondrial mass and coupling efficiency[53]. Consistent with the previous study [52], the 
expression level of PGC1α was significantly reduced in MCI cybrids compared to non-MCI 
cybrids (Fig. S6). In view of that PGC1α-deficient mice exhibit decreased mitochondrial 
number and decreased respiratory capacity [54], a decrease in PGC1α expression in MCI-
derived mitochondria might account for the altered mitochondrial dynamic and function. 
Further investigations are required for elucidation of the detailed mechanisms involved in 
PGC1α and MCI mitochondrial defects.
Mitochondrial functional defects manifest as altered mitochondrial morphology and 
distribution in MCI cybrids. These lines demonstrate significant changes in mitochondrial 
morphology and fission/fusion balance. Morphologically, mitochondria in MCI cybrids are 
larger and less dense than they are in non-MCI cybrids. We explored the involvement of 
abnormal mitochondrial dynamics by investigating the expression of mitochondrial fission 
and fusion proteins in MCI cybrids, and found increased Mfn2 levels in MCI cybrid 
mitochondria. Given that mitochondrial Mfn2 is involved in mitochondrial fusion [25], 
increased mitochondrial Mfn2 levels in MCI cybrids suggests altered Mfn2 expression likely 
contributes to enhanced mitochondrial fusion. Indeed, no changes in other mitochondrial 
fission and fusion markers including Fis1, Opa1, and Drp1 levels were found in MCI 
cybrids compared to non-MCI cybrid cells. The mitochondrial Fis1 and Opa1 levels 
remained comparable between MCI and Non-MCI cybrids, which were consistent with the 
results shown by Silva et al. [52]. Although most of our results were consistent with the 
observation of the Silva et al. study, we displayed a different mitochondrial dynamic shifted 
direction. In Silva’s study, Drp1 levels of mitochondria trended higher in the MCI cybrid 
group than the control cybrid group. Drp1 serine 637 phosphorylation was reduced in the 
MCI group compared with control group. These results supported the author’s hypothesis 
that mitochondrial fission-fusion balance shifted towards increased fission in the MCI 
cybrids. On the other side, our study clearly showed Drp1 levels in mitochondria were 
comparable between Non-MCI and MCI groups. Further, we demonstrated for the first time 
that Mfn2 levels were higher in MCI cybrids than Non-MCI cybrids. Accordingly, changes 
in mitochondrial morphology were seen in MCI mitochondria as shown as elongated 
mitochondria. While the impact of MCI-derived mitochondrial defects on mitochondrial 
function, such as respiratory chain activity is well-proven in our and others’ studies, the 
discrepancy of Drp1 expression levels in MCI-cybrid cells between ours and Silva et al 
could be ascribed to the methodologies, such as individual patient variation, different 
methods for mitochondrial isolation, choice of reference proteins, and resources of 
antibodies. Nerveless, our present studies clearly showed alterations in mitochondrial fusion 
protein Mfn2 along with mitochondrial morphology MCI-derived mitochondria, which may 
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be responsible for a shift in a direction that favors mitochondrial fusion as seen in MCI-
derived mitochondria.
Perturbations in mitochondrial fusion and fission can lead to distinctive defects in neurons. 
Mitochondrial fusion likely protects function by facilitating mixing of mitochondrial 
contents, which results in protein complementation, mtDNA repair and proper distribution 
of metabolites [55]; however, overly fused mitochondria would increase oxidative damage 
and further transform into large spheres, which associates with impaired mitochondrial 
respiration and defective organelle transport [56]. Mitochondrial fusion might represent an 
early response to cellular stress that provides transient protection against apoptosis and 
mitophage [57, 58]. Our finding on enhanced mitochondrial fusion in MCI cybrids suggests 
that distinct changes in mitochondrial morphology occur very early during the evolution of 
AD, and certainly as early as the MCI stage.
In view of the known significance of oxidative damage in the development of AD [40, 59], 
and the unexplored role of oxidative stress in MCI, we further explored the effect of 
oxidative stress on altered mitochondrial function by using the antioxidant probucol to 
scavenge ROS in cybrids. Our results indicate remarkable improvements in mitochondrial 
membrane potential, respiratory chain complex activity, and ATP production. Importantly, 
the elevated intracellular and mitochondria ROS production/accumulation contributes 
importantly to altered mitochondrial fission and fusion induced by MCI subject-derived 
mitochondria. Treatment of the antioxidant probucol rescued abnormal mitochondrial 
morphology by influencing mitochondrial fission and fusion balance and associated protein 
expression levels, indicating that increased oxidative stress in MCI mitochondria is 
responsible for perturbing mitochondrial dynamics, which in turn alters mitochondrial 
structure and function. The mild increase in ROS could also activate mitochondrial fusion 
[57, 60], aiming at compensation for the decreased mitochondrial function as observed in the 
MCI cases, the pre-stage of AD. Since MCI infers an increased risk of AD, antioxidant 
treatment that specifically target mitochondrial ROS may prove useful for MCI therapy and 
reduce the incidence of conversion from MCI to AD.
ROS-induced activation of the mitogen-activated protein (MAP) kinase family appears to 
play a key role in mediating cellular responses to multiple stresses [61]; ERK signaling is 
involved in mitochondrial function and neuronal stress [43, 62, 63]. In the present studies, 
ERK1/2 phosphorylation was significantly increased in MCI cybrids, and probucol blocked 
ERK1/2 activation and attenuated mitochondrial dysfunction. These data implicate a role for 
ERK1/2 signal transduction in altered MCI cybrid mitochondrial function.
Mitochondrial fusion may represent an early response to cellular stress [57, 58]. Up-
regulated Mfn2, which should facilitate mitochondrial fusion, likely protects cells 
confronted by ROS accumulation [64]. Little is known about oxidative stress-associated 
signal transduction pathways that may regulate the mitochondrial fusion/fission dynamics in 
MCI subject-derived mitochondria. We reveal that blockade of ERK1/2 activation rescues 
mitochondrial morphology by suppressing mitochondrial Mfn2 levels in MCI cybrids. We 
therefore propose that Mfn2 up-regulation is induced by oxidative stress-mediated ERK 
activation, which in turn shifts mitochondrial dynamics towards fusion in MCI-derived 
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cybrids. An altered balance of mitochondrial fission and fusion is likely an important 
mechanism leading to mitochondrial and neuronal dysfunction in AD as well as in MCI 
[25]. In our previous study of AD cybrid cells, ERK inhibition restored a proper balance 
between mitochondrial fission and fusion, which associated with recoveries in mitochondrial 
morphology and function, thereby demonstrating a pivotal upstream role for ERK in the 
regulation of AD cybrid mitochondrial dynamics and function [40]. Here, we extend this 
line of investigation to MCI and find that ERK blockade improves the function of 
mitochondria derived from MCI subjects. This implicates a role for ERK in mediating 
oxidative stress-associated mitochondrial dysfunction in MCI.
Lastly, our data suggest that preventing Mfn2 overexpression in MCI reverses perturbed 
mitochondrial dynamics by restoring mitochondrial density and mitochondrial length. 
Additionally, reducing Mfn2 levels by siRNA knockdown protected neurons from MCI 
mitochondria-mediated injury with secondary improvements in mitochondrial respiratory 
function and membrane potential. These results indicate that Mfn2 plays a critical role in 
mitochondrial dynamic imbalance and dysfunction in MCI mitochondria.
In human AD brain and mouse models, mitochondrial morphology shifts towards excess 
fission [36, 50]. Similarly, results of our previous studies showed an increase in 
mitochondrial fission and a decrease in mitochondrial fusion in AD cybrid cells [40]. Our 
unexpected finding of enhanced mitochondrial fusion in MCI cybrids in the present study 
suggests that mitochondria may react to early stress by favoring fusion in MCI. This may 
suggest a strategy for differentiating between MCI and AD at the molecular level. While 
MCI is clinically differentiated from AD by the severity of cognitive impairment, our 
current study indicates that Mfn2 is paradoxically up-regulated in MCI, but down-regulated 
in mitochondrial fractions from AD cybrids. We hypothesize that in AD, mitochondria 
dynamics are decompensating and lead to deteriorating conditions in favor of fission, but in 
MCI, the mitochondrial fission/fusion balance leans towards fusion as a compensatory and 
probably reversible condition. Our findings therefore suggest that in terms of mitochondrial 
dynamics, MCI and AD are qualitatively different.
Taken together, we demonstrated that Mfn2 expression is markedly induced by oxidative 
stress-mediated ERK1/2 signal transduction and plays a critical role in promoting 
mitochondrial structural and functional deficits in human MCI-derived cybrid cell lines. We 
hypothesize that oxidative stress is an early pathological event that is present even during 
the MCI stage of AD. Oxidative stress-mediated activation of ERK signal transduction 
disrupts mitochondrial fission and fusion balance and alters mitochondrial function. 
Suppression of ERK signaling may restore mitochondrial morphology and functional 
deficits present during MCIs. Up-regulation of Mfn2, a downstream consequence of ROS-
mediated ERK activation, triggers mitochondria fusion and perturbs mitochondrial dynamics 
(Fig. 7). Our studies suggest that the MCI stage of AD may offer unique opportunities for 
therapeutic development, and justify targeting oxidative stress and mitochondrial dynamics 
for the prevention of AD.
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Abnormal mitochondrial morphology in MCI cybrid cells. Cybrid cells were labeled with 
Mitotracker Red for visualization of mitochondrial morphology. (A1–A3) Quantitative 
measurement of mitochondrial density (using NIH ImageJ software) presented as the 
percentage of area occupied by mitochondria in entire cells (A1), neuronal process (A2), or 
cell body (A3). (B1–B3) Average mitochondrial length throughout the entire cell, neuronal 
processes, and cell body was higher in MCI cybrid cells compared to Non-MCI cells. (B4) 
Quantification of mitochondrial size based on the grouped differently sized bins. (C) 
Representative images of Mitotracker Red staining. Lower panels present larger images 
corresponding to the indicated images above. Scale bar = 5 µm. N = 7 cell lines/group. (D–
E) Drp1 and Mfn2 expression levels in Non-MCI and MCI cybrid mitochondria. 
Densitometry of immunoreactive bands for Drp1 (D) and Mfn2 (E) in mitochondrial 
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fractions of the indicated groups of cybrid cells. Data are expressed as fold-increase of Drp1 
or Mfn2 relative to Non-MCI cells. Drp1 andMfn2 levels were normalized to mitochondrial 
marker Hsp60. Representative immunoblots are shown underneath. N = 7 cell lines/group.
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Mitochondrial dysfunction in MCI cybrid cells. (A–D) Enzymatic activity of complex I, III, 
and IV (CcO), and ATP levels were determined in cell lysates from indicated cell groups. 
(E–F) Mitochondrial membrane potential and reactive oxygen species (ROS) were 
measured by tetramethylrhodamine methyl ester (TMRM) (E) and Mitosox staining 
intensity (F), respectively. Image intensity was quantified using NIH ImageJ software. (G) 
The production of the intracellular ROS determined by EPR spectroscopy in Non-MCI and 
MCI cybrids. (H) Representative spectra of EPR. The peak height in the spectrum indicates 
the level of reactive oxygen species (ROS). Data are expressed as fold increase relative to 
Non-MCI cybrid cells. N = 7 cell lines/group.
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Effect of antioxidant treatment on mitochondrial function and morphology. (A–C) Cells 
were treated with probucol (10 µM) for 24 h and then stained with Mitosox to determine 
mitochondrial ROS levels, or tested EPR values to evaluate intracellular ROS production. 
Quantification of staining intensity for Mitosox (A), EPR values (B), and representative 
EPR spectra (C). Mitochondrial membrane potential was shown as the quantification of 
staining intensity of TMRM (D) and representative images with TMRM staining (Scale bar 
= 10 µm) (E). (F–G) Complex I activity (F) and ATP levels (G) were measured in the 
indicated groups of cells with or without probucol treatment. Data are expressed as fold 
increase relative to vehicle treated Non-MCI cybrid cells. N = 7 cell lines/group.
Gan et al. Page 19














(A–B) Quantitative measurement of mitochondrial density (A) and average mitochondrial 
length (B) in the indicated cell groups using NIH ImageJ software. (C) Representative 
images of Mitotracker Red staining. Lower panels present larger images corresponding to 
the indicated images above (Scale bar = 5µM). (D) Quantification of immunoreactive bands 
for Mfn2 relative to Hsp60 in the indicated cell groups with probucol or vehicle treatment 
using NIH ImageJ software. Data are expressed as fold increase relative to vehicle-treated 
Non-MCI cybrid cells. Representative immunoblots are shown in the lower panel. N = 5–7 
cell lines/group.
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Inhibition of ERK activation rescued abnormal mitochondrial function and morphology. (A–
B) Densitometry of immunoreactive bands for phospho-ERK1/2 (p-ERK1/2) using NIH 
Image J software, normalized to total-ERK1/2 (t-ERK1/2) in indicated cell groups treated 
with PD98059 (10 µM for 2 h) (A), probucol (10 µM for 24 h) (B), or vehicle. 
Representative immunoblots are shown in lower panel. (C) PD98059 treatment decreased 
Mitosox staining intensity in MCI cybrid cells compared to vehicle treatment. (D–E) 
PD98059 treatment decreased intracellular ROS production in MCI cybrids compared to 
vehicle treatment measured by EPR. Quantification of EPR values in the indicated cybrid 
cells (D). (E) Representative EPR spectra. (F) TMRM staining intensity was significantly 
increased in MCI cybrid cells treated with PD98059. (G–I) Effects of ERK inhibitor on 
mitochondrial morphology. Representative images are shown for Mitotracker Red staining. 
The lower panel is a larger image corresponding to the indicated image above (Scale bar = 5 
µm) (G). Mitochondrial density (H) and average length (I) were measured in the indicated 
cell groups treated with PD98059 or vehicle. (J) Quantification of immunoreactive bands for 
Mfn2 normalized to Hsp60 in mitochondrial fractions of the indicated cell group with 
PD98059 or vehicle treatment. Representative immunoblots are shown in lower panel. Data 
are expressed as fold increase relative to vehicle-treated Non-MCI cybrid cells. N = 5–7 cell 
lines/group.
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Effect of Mfn2 blockade on MCI mitochondrial morphology and function. (A) 
Quantification of immunoreactive bands for Mfn2 normalized to β-actin in MCI cybrid cell 
lysate of the indicated group with siRNA-control and siRNA-Mfn2 transfection. 
Representative immunoblots are shown in the lower panel. Data are expressed as fold 
increase relative to siRNA-control transfected MCI cybrid cells. (B) MCI cybrid cells were 
transfected with siRNA-control or siRNA-Mfn2. After 24 h, cells were incubated with 
Mitotracker Red to analyze mitochondrial morphology using confocal microscopy (Scale 
bar = 5 µm). siRNA-Mfn2 transfected MCI cybrids had tubular mitochondria, whereas 
siRNA-control transfected cells retained elongated mitochondrial morphology. 
Mitochondrial average density (C), length (D), and CcO activity (E), and mitochondrial 
membrane potential (TMRM) (F) were restored in siRNA-Mfn2 transfected cells compared 
to siRNA- transfected control cells. ROS production measured by Mitosox (G) and EPR 
values (H, I) were suppressed in siRNA-Mfn2 transfected cells compared to siRNA-
transfected control cells. (H) Quantification of EPR values in the indicated groups of cells. 
(I) Representative EPR spectra. (J,K) Representative images for Mitotracker and Mitosox 
staining are shown (Scale bar = 10 µm). N = 5–7 cell lines/group.
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Schematic diagram showing sequence in which defects in MCI mitochondrial respiratory 
function result in increased mitochondrial ROS generation/accumulation stems; this in turn 
leads to activation of ERK signal transduction. ERK activation directly or indirectly disrupts 
the balance of mitochondrial dynamics (fusion and fission events) and results in altered 
Mfn2 expression levels, eventually leading to aberrant mitochondrial morphology and 
function. Genetic knockdown of Mfn2 expression rescues perturbation of mitochondrial 
morphology and function relevant to MCI mitochondrial degeneration.
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